Eli Lilly (LLY) Long-Term Investments (2009 - 2026)

Eli Lilly has reported Long-Term Investments for 18 years, with the latest figure at $3.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Long-Term Investments fell 3.31% year-over-year to $3.1 billion; the trailing twelve-month figure through Mar 2026 stood at $3.1 billion (down 3.31% YoY), and the FY2025 full-year result was $2.8 billion, down 12.87% from the prior year.
• Long-Term Investments for Q1 2026 stood at $3.1 billion, up from $2.8 billion in the prior quarter.
• The five-year high for Long-Term Investments was $3.2 billion in Q1 2025, with the low at $2.6 billion in Q3 2022.
• Historically, Long-Term Investments has averaged $2.9 billion across 5 years, with a median of $2.9 billion in 2024.
• Annual changes were most pronounced in 2022 — Long-Term Investments dropped 25.55% — and 2024, when it advanced 18.89%.
• Eli Lilly's Long-Term Investments stood at $2.9 billion in 2022, then advanced by 5.18% to $3.1 billion in 2023, then advanced by 5.37% to $3.2 billion in 2024, then declined by 12.87% to $2.8 billion in 2025, then increased by 11.21% to $3.1 billion in 2026.
• The last three Long-Term Investments figures came in at $3.1 billion (Q1 2026), $2.8 billion (Q4 2025), and $2.8 billion (Q3 2025), per Business Quant data.